Eluminex Biosciences’ Acquisition of Zuretinol Acetate Assets from Retinagenix

Goodwin Procter advised Eluminex Biosciences on the deal. Eluminex Biosciences (Suzhou) Limited (Eluminex) announced its acquisition of certain assets and the related global development and commercialization rights...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here